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Background. Cholesterol homeostasis is maintained through finely tuned mechanisms regulating intestinal absorption,
hepatic biosynthesis and secretion as well as plasma clearance. Proprotein convertase subtilisin/kexin type 9 (PCSK9) is
a secreted enzyme of the serine protease family that reduces cellular uptake of plasma low-density lipoprotein (LDL)
cholesterol by promoting LDL receptor (LDL-R) degradation. Species-specific positive selection has been noted in the LDLR
promoter, leading to differential expression of LDLR among primates. Whether PCSK9 experienced significant selective
pressure to maintain a functional relationship with its target protein, LDL-R, is unknown. Methodology/Principal Findings.
We compiled the sequences of the coding regions of PCSK9 from 14 primate species in the clade of Hominoids, Old World
monkeys and New World monkeys. To detect selective pressure at the protein level, the ratios of nonsynonymous/synonymous
substitution rate (dN/dS) under different evolutionary models were calculated across the phylogeny of PCSK9. Maximum
likelihood analyses of dN/dS ratios for the aligned coding region sequences among 14 primate species indicated that PCSK9
was subject to a strong functional constraint (i.e., purifying selection). However, positive selection was noted in the functional
carboxyl-terminal (C-terminal) domain in many branches across the phylogeny, especially in the lineage leading to the
orangutan. Furthermore, at least five positively selected amino acids were detected in this lineage using the branch-site model
A. In a sliding-window analysis, several dN/dS peaks in the C-terminal domain in both the human and the orangutan branches
were noted. Conclusions. These results suggest that among primates, differential selective pressure has shaped evolutionary
patterns in the functional domains of PCSK9, an important regulator of cholesterol homeostasis.
Citation: Ding K, McDonough SJ, Kullo IJ (2007) Evidence for Positive Selection in the C-terminal Domain of the Cholesterol Metabolism Gene PCSK9
Based on Phylogenetic Analysis in 14 Primate Species. PLoS ONE 2(10): e1098. doi:10.1371/journal.pone.0001098
INTRODUCTION
The low-density lipoprotein (LDL) receptor gene (LDLR)p l a y sak e y
role in cholesterol homeostasis by receptor-mediated endocytosis of
LDL cholesterol. Proprotein convertase subtilisin/kexin type 9
(PCSK9, MIM 607786) – a secreted enzyme of the serine protease
family – is a newly discovered regulator of LDLR [1–3]. The human
PCSK9 locus spanning 25 kb and containing 12 exons, resides on
chromosome 1p32. The PCSK9 protein contains five functional
domains,a signal-peptideandprodomain at itsN-terminus, followed
by a catalytic domain, a putative domain and a cysteine-rich
carboxy-terminal domain [4–6] (Figure 1). PCSK9 induces LDL-R
breakdown [7], internalization and recycling [8,9] and thereby
reduces LDL clearance, and increases plasma levels of LDL
cholesterol. Overexpression of wild-type Pcsk9 gene in mice results
in reduced number of LDL-R and hypercholesterolemia [4,8,9].
Mutations in PCSK9 can cause severe autosomal dominant
hypercholesterolemia [4,8–14] (i.e., ‘gain-of-function’ mutations),
and also low circulating levels of LDL cholesterol [15–19] (i.e., ‘loss-
of-function’ mutations). Kotowski et al. [17] described a spectrum of
nonsense/missense mutations in PCSK9 that were associated with
low or elevated LDL cholesterol levels, in both black and white
subjects. Relatively common sequence variants in PCSK9 also
contribute significantly to inter-individual variation in plasma levels
of LDL cholesterol in the general population [17]. Cohen et al. [20]
showed that two nonsense mutations (Y142X and C679X) in blacks,
and one missense mutation (R46L) in whites, were associated with
reduced plasma levels of LDL cholesterol and lower incidence of
coronary heart disease events. We have summarized these non-
synonymous variations in PCSK9 in Figure 1.
Extant primates show a wide range of phenotypic adaptations to
diverse environmental conditions, including substrate and diet
[21]. Significant differences in lipid profiles occur among primates;
for example, New World and Old World monkeys have
significantly lower serum total cholesterol, triglycerides, and
LDL cholesterol levels than Hominoids [22]. Among Hominoids,
gorillas have the highest circulating total cholesterol, triglycerides,
and high-density lipoprotein (HDL) cholesterol levels [22].
Caceres et al. [23] found that several genes related to lipid
metabolism were differentially expressed in humans and non-
human primates. LDLR has also been shown to be differentially
expressed among mammals [24].
Activation of the sterol regulatory element binding protein-2
(SREBP-2), a key transcription factor of LDLR, not only leads to
increased expression of LDLR, but also of PCSK9 [25], and the
mRNA expression of LDLR and PCSK9 are coordinately up-
regulated in absence of sterols [26]. The dual regulation of LDLR
[26] suggests that PCSK9 might be involved in a co-evolutionary
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evolving with variation at the other. PCSK9 is only found in
vertebrates, suggesting it is the product of recent evolution [27].
However, it is unclear whether natural selection has driven the
evolution of PCSK9 in vertebrates, especially in primates.
The ratio of nonsynonymous/synonymous substitution rate (i.e.,
v=dN/dS) provides a sensitive measure to detect selective pressure
at the protein level [28]. A significantly higher non-synonymous
substitution rate than synonymous substitution rate (i.e., dN/dS.1)
is evidence for adaptive evolution at the molecular level, whereas
dN/dS,1 suggests purifying selection (i.e., selective constraint)
[29]. This criterion has been used to identify several cases of
positive selection, such as the primate stomach lysozyme (LYZ)
[30,31], and BRCA1 in humans and chimpanzees [32] (for a list of
genes under positive selection in the human lineage, see review by
Sabeti et al. [33]).
In the present study, we used a phylogeny-based maximum
likelihood method to analyze nonsynonymous and synonymous
substitution rate of PCSK9 sequences across a range of primates,
including Hominoids, Old World monkeys, and New World
monkeys. We aimed to address three questions: 1) whether the
ratio of nonsynonymous and synonymous evolutionary rate of
PCSK9 varied significantly among various primate lineages, 2)
whether there is an episodic adaptive evolution of PCSK9 in
primates, and 3) which, of any, amino acids of PCSK9 were under
positive selection.
RESULTS
Comparative analysis of coding regions of PCSK9
We characterized the coding regions of PCSK9 in human and non-
human primates (Table 1). There was considerable evidence for
interspecies genomic alterations within PCSK9 (Figure 2). First, in
the signal peptide domain, a variable number of CTG codons
[encoding Leucine (Leu, L)] were identified (Figure 2). A species-
specific nine Leu repeat (L9) was noted only in humans and
chimpanzee; whereas in other species, the number of Leu repeats
varied from L6 to L8. In the CTG repeat region, interspecies
nucleotide differences were synonymous except nonsynonymous
changes in the Old World monkeys (CTGRCCA, 46R48) and in
spider monkey (CTGRCGG, 67R69). Second, in the C-terminal
domain, species-specific loss-of-function mutation was seen in the
clade of New World monkeys (via a premature stop codon in
tamarin and dusky titi). We speculate that this nonsense mutation
leads to a loss-of-function since the adjacent C679X mutation in
humans is a loss-of-function mutation.
Variable dN/dS ratios for the C-terminal domain of
PCSK9 among primate lineages
A neighbor-joining (nj) phylogenetic tree of PCSK9 from 14
primate species was reconstructed from the coding sequence
alignment, and the maximum likelihood estimate of the tree
topology was acquired using the ‘hyphy’ package [34]. We used
this gene tree in subsequent analyses to detect whether non-neutral
evolution might have operated on PCSK9.
Under a one-ratio model, which assumes the same dN/dS for the
entire tree, the cumulative dN/dS for the coding regions of PCSK9
was 0.186 (the log likelihood value l0=25109.09). We tested
variable dN/dS ratios for PCSK9 among lineages, using the free-
ratio model, which assumes a different dN/dS ratio for each branch
in the phylogeny (Figure S1). The free-ratio model led to a log
likelihood l1=25097.59. The free-ratio model was not found to
Figure 1. Distribution of non-synonymous variations along PCSK9. There are five functional domains in the PCSK9 protein [4–6]: 1) a signal peptide
(SP) (1,30 aa), 2) a prodomain (31,147 aa), 3) a catalytic domain (148,425 aa), 4) a putative P domain (426,525 aa), and 5) a C-terminal domain
(526,691 aa). Gain-of-function mutations are only identified in families with hypercholesterolemia [10] or subjects with high LDL cholesterol levels
[17], and loss-of-function mutations in subjects with low levels of LDL cholesterol [15–19]. Some non-synonymous mutations have been identified in
subjects with either high or low plasma LDL cholesterol [4,17], and are labeled ‘both’ in the figure. Rare mutations found in families with autosomal
dominant hypercholesterolemia are labeled with an asterisk. The gain-of-function mutations are: S127R, F216L, R237W, D374Y, H417Q, R469W,
E482G, F515L and H553R. The loss-of-function mutations are: 14insL, E57K, Y142X, L253F, H391N, Q554E, and C679X. Mutations associated with either
high- or low- plasma levels of LDL cholesterol subjects are: R46L, A53V, N425S, A443T, I474V, Q619P, and E670G.
doi:10.1371/journal.pone.0001098.g001
Table 1. A listing of the primates in this study.
......................................................................
Species Scientific name Lineage
Accession
number
Human Homo sapiens Hominoid EF692496
Chimpanzee Pan troglodytes Hominoid EF692497
Bonobo Pan paniscus Hominoid EF692498
Gorilla Gorilla gorilla Hominoid EF692499
Orangutan Pongo pygmaeus Hominoid EF692500
Pigtailed macaque Macaca nemestrina Old World Monkey EF692501
Rhesus macaque Macaca mulatta Old World Monkey EF692502
Colobus Colobus guereza Old World Monkey EF692503
Dusky titi Callicebus moloch New World Monkey EF692504
Tamarin Saguinus labiatus New World Monkey EF692505
Marmoset Callithrix jacchus New World Monkey EF692506
Squirrel monkey Saimiri boliviensis New World Monkey EF692507
Spider monkey Ateles geoffroyi New World Monkey EF692508
Woolly monkey Lagothrix lagotricha New World Monkey EF692509
doi:10.1371/journal.pone.0001098.t001
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PLoS ONE | www.plosone.org 2 October 2007 | Issue 10 | e1098**** *** ***** ****** * .*:****::*.*************:* .:* ::*:*********:.************ .::: *.***************** *:***** *******
            Human MGTVSSRRSWWPLPLLLLLLLLLGPAGARAQEDEDGDYEELVLALRSEEDGLAEAPEHGTTATFHRCAKDPWRLPGTYVVVLK-EETHLSQSERTARRLQAQAARRGYLTKILHVFHGLLPGFLV
       Chimpanzee ...................................................................................-.........................................
          Gorilla ..............--...................................................................-.........................................
           Bonobo ..............--...................................................................-.........................................
        Orangutan ..............--...........................................A.......................-....R............................D.......
Pigtailed_Macaque ...............P.....................................D.....A.......................-....R............................H.......
   Rhesus_Macaque ...............P.....................................D.....A.......................-....R............................H.......
          Colobus ...............P........L............................D.....A.......................-....R............................H.......
       Dusky_Titi ........L.....--.........P.......D.................P.D.LQ..A.......................DSDA.R..P.................I.L.....H.......
          Tamarin ........L.....--...........T.....D.D.............E...D.LQN.A.......................-....R..P.................I.L.....D.......
         Marmoset ........L.....--.........T.T....ED.D................VD.LQ..A..........S............-....R..P.................I.L.....D.......
  Squirrel_Monkey ........L......-.................D...................D.LQ..A.........E.............-....R..P.................I.L.....D.......
    Spider_Monkey ....R...L.....--......R..........D......................Q..A.......................-...QR..P.................I.L.....D.......
    Woolly_Monkey ....R...L.....--.................D.....................LQ..A.......................-...QRL.P.................I.L.....D.......
            ruler 1.......10........20........30........40........50........60........70........80........90.......100.......110.......120.....
*** *******:*********** ***************.**:*******.****************.************* .**:***********************************.::*
            Human KMSGDLLELALKLPHVDYIEEDSSVFAQSIPWNLERITPPRYRADEYQPPDGGSLVEVYLLDTSIQSDHREIEGRVMVTDFENVPEEDGTRFHRQASKCDSHGTHLAGVVSGRDAGVAKGASMRS
       Chimpanzee .............................................................................................................................
          Gorilla .............................................................................................................................
           Bonobo .............................................................................................................................
        Orangutan .............................................................................................................................
Pigtailed_Macaque .......................................A..........K...............................S......................................GL..
   Rhesus_Macaque .......................................A..........K...............................S......................................GL..
          Colobus .......................................A..........K...............................S......................................GL..
       Dusky_Titi ...R.......R...........................A..........N................S..............S.......................................L..
          Tamarin ...R.......R...........................A..Q.......N................G.............GS..K....................................LH.
         Marmoset ...R.......R...........................A..........N................G.............GS.......................................L..
  Squirrel_Monkey ...R...................................A..........N................G.............GS.......................................L..
    Spider_Monkey ...R.......R...........Y...............A..........N................G..............S.......................................L..
    Woolly_Monkey ...R.......R...........Y...............A..........N................G..............S.......................................L..
            ruler ..130.......140.......150.......160.......170.......180.......190.......200.......210.......220.......230.......240.......250
*:***********.:******* *.************:*********:****:*** * ****:********************************:****************************
            Human LRVLNCQGKGTVSGTLIGLEFIRKSQLVQPVGPLVVLLPLAGGYSRVLNAACQRLARAGVVLVTAAGNFRDDACLYSPASAPEVITVGATNAQDQPVTLGTLGTNFGRCVDLFAPGEDIIGASSD
       Chimpanzee .............................................................................................................................
          Gorilla .............................................................................................................................
           Bonobo .............................................................................................................................
        Orangutan .....................................M.......................................................................................
Pigtailed_Macaque ...............................................F.............................................................................
   Rhesus_Macaque ...............................................F.............................................................................
          Colobus ...............................................F.............................................................................
       Dusky_Titi .H...........SA.....................................R...G......A................................L............................
          Tamarin .............S........C...................................R....A.............................................................
         Marmoset .............S.................................................A.............................................................
  Squirrel_Monkey .............S.................................................A.............................................................
    Spider_Monkey .............S..........N...............................K......A.............................................................
    Woolly_Monkey .............S..........N......................................A.............................................................
            ruler .......260.......270.......280.......290.......300.......310.......320.......330.......340.......350.......360.......370.....
*******:***************:***.:***********************.***************:****** **********************:.*** *********** **:****:
            Human CSTCFVSQSGTSQAAAHVAGIAAMMLSAEPELTLAELRQRLIHFSAKDVINEAWFPEDQRVLTPNLVAALPPSTHGAGWQLFCRTVWSAHSGPTRMATAIARCAPDEELLSCSSFSRSGKRRGER
       Chimpanzee ...................................................................................................V.........................
          Gorilla ...................................................................................................V........................H
           Bonobo ...................................................................................................V........................H
        Orangutan ...........................V........................V........................................................................
Pigtailed_Macaque .......R...................................................................R.......................V....Q....................
   Rhesus_Macaque .......R...................................................................R.......................V....Q....................
          Colobus .......R...................................................................R.......................VV........................
       Dusky_Titi .......R............................................................T..............................M.........................
          Tamarin .......R....................................................................E......................M.........................
         Marmoset .......R....................K......................................................................M...................R.....
  Squirrel_Monkey .......R...............V...........................................................................M................S........
    Spider_Monkey .......R...........................................................................................M.........................
    Woolly_Monkey ...................................................................................................M.........................
            ruler ..380.......390.......400.......410.......420.......430.......440.......450.......460.......470.......480.......490.......500
::****: ** * *****:** *:********.***:****** :.****. **:* *:*****:***:::******.:*:* * .**:** ** **:** ************:******* *
            Human MEAQGGKLVCRAHNAFGGEGVYAIARCCLLPQANCSVHTAPPAEASMGTRVHCHQQGHVLTGCSSHWEVEDLGTHKPPVLRPRGQPNQCVGHREASIHASCCHAPGLECKVKEHGIPAPQEQVTV
       Chimpanzee ....................................I........G................................M.......................R......................
          Gorilla .............................................G...............................................................................
           Bonobo .............................................G...............................................................................
        Orangutan .....................C.....................GSG.....L....V.............................................R......................
Pigtailed_Macaque I......R........................V..........G...............................................................................I.
   Rhesus_Macaque I......R........................V..........G...............................................................................I.
          Colobus I......R........................V..........G...............................................................................I.
       Dusky_Titi I.....RR..L.P..........V...................G.G....A.................MK..........K.....D..M..SG..T.....Y............L.........
          Tamarin I.....RR..L................................G.G....A.......I.......................E..H...M...G..T..................L.........
         Marmoset I.....RR..L................................G.G....A.......I.......................G..HD..M...G..T..................L.........
  Squirrel_Monkey I.....RR..L.......K.................I......G......A.............A.....E...........G...S..M..SG..T..T...............L.........
    Spider_Monkey IK....RR..L................................G.G........H......................S.....V..D..M..SG..T..................L.........
    Woolly_Monkey I..........................................GTG.....................................V..D..M..SG..T..................L.........
            ruler .......510.......520.......530.......540.......550.......560.......570.......580.......590.......600.......610.......620.....
:**:*******..******:****.:*:******:*:.*:. *:::::::***** **. ** :**
            Human ACEEGWTLTGCSALPGTSHVLGAYAVDNTCVVRSRDVSTTGSTSEEAVTAVAICCRSRHLAQASQELQ
       Chimpanzee .......................................A........A...................
          Gorilla ........................GI...............R.....LA...........V.......
           Bonobo ........................GI...............R.....LA...........V.......
        Orangutan ....................................I..........MA.......R...........
Pigtailed_Macaque ...D............................................A...........V.......
   Rhesus_Macaque ...D........P...............................K...A...........V.......
          Colobus ...D.......N...................................MA...........V.......
       Dusky_Titi ...........................D....................A............X...D..
          Tamarin T..........................D..................T.A........Q......X...
         Marmoset T..................I.......D............S.....T.AT.......Q..........
  Squirrel_Monkey ...................I.......D......Q.............A...................
    Spider_Monkey ...........................D.............N...Q..A...................
    Woolly_Monkey ...........................D.........G...NI..............W..........
            ruler ..630.......640.......650.......660.......670.......680.......690...
Figure 2. Protein sequence alignment of PCSK9 in 14 primates. ‘‘.’’ Indicates identity to the first sequence (i.e., human) in each alignment. ‘‘-’’
indicates an alignment gap, and ‘‘X’’ indicates a stop codon. The coordinates after 84 should be minus one to be consistent with that in Human
reference sequence (NP_777596), since an insertion at position 84 was present in the dusky titi. The signal peptide (SP) domain (1–90) shows the
evolution of Leucine (Leu) repeats (15–23) in PCSK9, and the C-terminal domain shows the premature stop codon (X) in the tamarin (686), and dusky
titi (689).
doi:10.1371/journal.pone.0001098.g002
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2Dl=2(l12l0), P=0.480, degrees of freedom (df)=24).
In addition to testing the entire coding regions, it is important to
test the structural and functional domains of proteins separately
[35]. We evaluated selective pressures in different structural and
functional domains by repeating the dN/dS analyses within these
domains (the domain structure of PCSK9 is shown in Figure 1). For
the C-terminal domain of PCSK9, the free-ratio model
(l1=21351.35) was found to be significantly better than the
one-ratio model (l0=21369.71, the cumulative dN/dS=0.386)
(2Dl=36.72, P=0.047, df=24), suggesting variable selective
constraint across the phylogeny for the C-terminal domain
(Figure 3). We did not observe a significant difference between
these two models for each of the other four domains and when the
four domains were combined (data not shown).
Non-neutral evolution of the PCSK9 C-terminal
domain
Comparison of the rates of nonsynonymous and synonymous DNA
changes (i.e., the ratios of dN/dS) between species can be used to
assess the types of selective pressures that may have acted on a gene
[36]. In the entire PCSK9 sequence, dS exceeded dN in most of the
branches in the primate phylogeny (dN/dS,1.0) (Figure S1),
indicating that functional constraint (i.e., purifying selection) might
haveactedonPCSK9throughoutprimateevolution.Inthebranchof
bonobo and gorilla, the dN/dS ratio was=1 (i.e., neutral evolution).
We then compared the values of dN and dS between species in
the C-terminal domain of PCSK9 since non-homogeneity in dN/dS
ratio was noted among the primate lineages. We found that many
branches of the primate phylogeny, including internal branches,
showed evidence of evolution under relaxed selective constraint or
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Figure 3. Ratios of dN/dS estimated for the C-terminal domain of PCSK9 in indicated branches of the primate phylogeny. Values of dN/dS along
each branch were calculated by using the free-ratio model using the CODEML program in ‘PAML’ [72]. Branch lengths were estimated by maximum
likelihood under this model. A dN/dS value of .1 suggests that positive selection has acted along that lineage. ‘Inf’ indicates cases where dS=0. The
phylogenetic tree was deduced from the entire coding sequence of PCSK9.
doi:10.1371/journal.pone.0001098.g003
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PLoS ONE | www.plosone.org 4 October 2007 | Issue 10 | e1098positive selection (i.e., dN/dS.1.0) (Figure 3). In the Hominoid
clade, dN/dS values was infinity (
N|dN
S|dS
: 7.1/0.0) in the lineage
leading to orangutan, and 1.218 (5.1/1.1) to the common
ancestors of bonobo and gorrila. The dN/dS in the chimpanzee
and human lineages approximated one [0.9890 (4.0/1.1) and
0.5657 (2.0/1.0), respectively], indicating relaxed selective con-
straint in these two lineages. In addition, we noted dN/dS.1i n
lineages leading to colobus and rhesus macaque in the clade of Old
World monkeys, as well as spider monkey, squirrel monkey, and
the common ancestors of marmoset and tamarin (Figure 3). Thus,
the C-terminal domain has been subject to positive selection for at
least 33 million years (i.e., the primate divergence time) [37].
Then, by two-ratio likelihood tests using PAML, we tested for
the presence of positive selection in the C-terminal domain of
PCSK9 in the branch of orangutan and the lineage leading to the
common ancestors of bonobo and gorilla in the Hominoid clade.
Log likelihood values and dN/dS estimates from each maximum
likelihood model were considered, and the likelihood ratio test
results are presented in Table 2. The null hypotheses 1–3 were
rejected, indicating that the dN/dS ratio in the branch of orangutan
is significantly higher than the background ratio of dN/dS (i.e., the
null hypothesis of dN/dS ratio homogeneity among lineages was
rejected). Although the alternative hypotheses of positive selection
(dN/dS.1) in the branch of orangutan (null hypotheses 7 and 8 in
Table 2) were not accepted at the level of 0.05, the statistical
significance was marginal (P=0.087 and 0.090, respectively).
However, we did not observe the dN/dS ratio in the lineage leading
to bonobo and gorilla to be significantly different from the
background dN/dS ratio.
To find out whether the C-terminal domain was under relaxed
selective constraint or positive selection, we also plotted dN/dS
ratios estimated by Nei-Gojobori method for pairwise comparisons
within the primates (Figure 4). In the whole gene sequence and
non C-terminal domains region, dN/dS was ,1 in all pairwise
comparisons, indicating a history of functional selective constraint.
However, a higher dN/dS value was noted in the C-terminal
domain, including dN/dS.1 in five out of 10 pairwise comparisons
within Hominoids. For example, a dN/dS ratio of 1.122 was noted
in the human vs. orangutan comparison.
Amino acids sites under positive selection
Finally, we identified the particular codon sites that have been
subject to positive selection using the site-models [38,39] and the
branch-site models [40]. Table 3 lists the log likelihood values and
parameter estimates for the C-terminal domain of PCSK9 under
several site models and branch-site models. We used two likelihood
ratio tests (LRTs) to test for positive selection. In the site models,
the first test compared M1a (neutral) against M2a (selection)
[38,40,41], in which 2Dl is 0.68 (df=2, P.0.05), and no amino
acid sites were under positive selection. The second test compared
M7 against M8, in which no sites were shown under positive
selection (2Dl=1.66, P.0.05). We also used the branch-site model
A to detect the codon sites under positive selection by the Bayes
Emprical Bayes (BEB) approaches in the lineage of orangutan (i.e.,
the foreground lineage) [40]. The 2Dl between the null model
(neutral, l=21366.56) and the alternative model (selection,
l=21363.55) is 6.02. The critical values at the 5% and 1% levels
for the LRT are 2.71 and 5.41, respectively [42]. Thus, the test for
the branch-site model A is significant (df=2, P,0.01), indicating
presence of codon sites under positive selection (544A, 551H,
556G, 661V, and 681S, Pb.95%) in the C-terminal domain of
PCSK9.
Sliding window analysis
The dN/dS profiles in the sliding window analysis across PCSK9
sequence are shown in Figure 5. As expected, the cumulated dN/dS
ratio in primates in the sliding window analysis appear quite
stochastic and bears weak correlation to the domain structure,
although the dN/dS is slightly higher in the C-terminal domain.
However, in the lineages leading to humans and orangutan, we
observed that nonsynonymous substitutions were significantly
more concentrated within C-terminal domain of PCSK9 (i.e., three
dN/dS peaks). The dN/dS peaks were consistent between the lineage
leading to humans and to orangutan.
Table 2. Log likelihood values, parameter estimates under different models, and likelihood ratio statistics (2D,) for dN/dS
hypotheses testing.
..................................................................................................................................................
Model Para
a ln l
b dN/dS (v) Model compared Null hypothesis 2DlP (x
2,d f=1 )
c
v0 vh vg
A. One ratio: v0=vh=vg 27 21369.71 0.3856 =v0 =v0 A vs. D 1. (vh=vg)=v0 6.24 0.012
*
B. Two ratios: v0=vh, vg 28 21366.30 0.3503 =v0 Inf A vs. B 2. vg=v0 6.82 0.009
*
C. Two ratios: v0=vg, vh 28 21369.21 0.3686 1.0106 =v0 C vs. E 3. vg=v0 7.02 0.008
*
D. Two ratios: v0, vh=vg 28 21366.59 0.3314 2.6347 =vh A vs. C 4. vh=v0 1.00 0.317
E. Three ratios: v0, vh, vg 29 21365.70 0.3326 1.0027 Inf B vs. E 5. vh=v0 1.20 0.273
F. Two ratios: v0=vh, vg=1 27 21367.76 0.3502 =v0 1.0000 D vs. H 6. (vh=vg)#1 1.10 0.394
G. Two ratios: v0=vg, vh=1 27 21369.21 0.3686 1.0000 =v0 B vs. F 7. vg#1 2.92 0.087
{
H. Two ratios: v0, vh=vg=1 27 21367.14 0.3324 1.0000 1.0000 E vs. I 8. vg#1 2.88 0.090
{
I. Three ratios: v0, vh, vg=1 28 21367.14 0.3324 1.0140 1.0000 C vs. G 9. vh#1 0.00 1.000
J. Three ratios: v0, vh=1,vg 28 21365.70 0.3326 1.0000 Inf E vs. J 10. vh#1 0.00 1.000
Note. – vh is dN/dS ratio in lineage leading to the common ancestor of gorilla and bonobo; vg is dN/dS ratio in lineage leading to orangutan; v0 is the background dN/dS
ratio.
aThe number of parameters estimated in the model.
bLog likelihood values.
cP values were obtained from the difference in the two log likelihood values of two models (2Dl) with x
2 distribution (df=1).
*Significant (P,0.05);
{ Significance is marginal (P,0.10).
doi:10.1371/journal.pone.0001098.t002
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The main finding of our study is that there is evidence for
functional constraint (i.e., purifying selection) in the coding
sequences of PCSK9 through primate evolution. We noted that
a functional domain of PCSK9 (i.e., C-terminal domain) was less
conserved at the amino acid level than other gene regions, and
likelihood ratio tests (LRTs) revealed evidence of positive selection
in the lineage leading to orangutan of the Hominoid clade on this
domain. Furthermore, we identified the particular codon sites that
have been subject to positive selection in this lineage. We discuss
the implications of these comparative sequence data for un-
derstanding the evolutionary history of primate PCSK9, hypotheses
concerning their role in primate phenotypic evolution, and insights
into PCSK9-associated human diseases.
Evolutionary history of Leucine (L) repeats in the
signal peptide (SP) domain and premature stop
codon in the C-terminal domain
Comparative sequence analysis revealed a dynamic evolutionary
history of leucine (Leu, L) repeats in the signal peptide domain.
The number of Leu repeats varied from L9 to L6 among different
0.00 0.05 0.10 0.15 0.20 0.25
0
.
0
0
0
.
0
5
0
.
1
0
0
.
1
5
0
.
2
0
0
.
2
5
Coding regions
dS
d
N
HOM~HOM
Human
HOM~NWM
HOM~OWM
OWM~OWM
OWM~NWM
NWM~NWM
0.00 0.05 0.10 0.15 0.20 0.25
0
.
0
0
0
.
0
5
0
.
1
0
0
.
1
5
0
.
2
0
0
.
2
5
Non C−terminal domain
dS
d
N
0.00 0.05 0.10 0.15 0.20 0.25
0
.
0
0
0
.
0
5
0
.
1
0
0
.
1
5
0
.
2
0
0
.
2
5
C−terminal domain
dS
d
N
Figure 4. Positive selection or relaxed selective constraint of the C-terminal domain of PCSK9. dN is plotted versus dS for all pairwise combinations
of primate sequences. The pairwise ratios of dN/dS were calculated using the Nei-Gojobori method implemented in the package ‘PAML’ [72]. Pairwise
combinations of Hominoids (HOM), Old World monkeys (OWM), and New World monkeys (NWM) are plotted; for example, ‘Human’ represents the
points that are making comparisons between human and another primate. We plotted the entire sequence, non C-terminal domain, and C-terminal
domain separately. The higher pairwise dN/dS ratio in the C-terminal domain suggests that this domain is evolving in a non-neutral model, which
maybe due to positive selection or relaxed selective constraint in some lineages. The entire sequence and non C-terminal domain of PCSK9 showed
a net signature of purifying selection.
doi:10.1371/journal.pone.0001098.g004
Table 3. Log likelihood values and parameter estimates under the site models and branch-site models.
..................................................................................................................................................
Model Para
a ln l
b Estimates of parameters 2Dl
c Positively selected sites
d
M0 (one-ratio) 1 21369.71 v0=0.3856 not allowed
Site models
M1a (Nearly Neutral) 2 21366.56 p0=0.7704 (p1=0.2296); v0=0.2110 (v1=1) not allowed
M2a (Positive Selection) 4 21366.22 p0=0.9032; p1=0(p2=0.0968); v0=0.2736 (v1=1),
v2=1.7797
(M1a vs. M2a) 0.68 none
M7 (beta) 2 21367.06 p=0.6432; q=0.9806 not allowed
M8 (beta & v)5 21366.23 p0=0.9054; p=37.7260; q=99.0000 (p1=0.0947);
v=1.7952
(M7 vs. M8) 1.66 none
Branch-site models
M1a 2 21366.56 p0=0.7704 (p1=0.2296); v0=0.2110 (v1=1)
Model A 4 21363.55 p0=0;p1=0.7632 (p2=0.2368); v0=0.1827 (v1=1),
v2=Inf
(M1a vs. Model A) 6.02
** 544A, 551H, 556G, 661V, 681S
aThe number of parameters estimated in the model.
bLog likelihood values.
cLRT to detect positive selection
** P,0.01.
dAmino acid sites under positive selection based on a Bayes Empirical Bayes (BEB) probability .95%. No amino acids sites under the model M2a and M8 were shown to
be under positive selection.
doi:10.1371/journal.pone.0001098.t003
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PLoS ONE | www.plosone.org 6 October 2007 | Issue 10 | e1098clades (Figure 2). An additional in-frame insertion (CTG) leading to
aL 9 RL10 polymorphism in African-Americans and Caucasians
[19] is associated with hypocholesterolemia. We speculate that the
number of Leu repeat may influence levels of the PCSK9 protein and
thereby levels of LDL cholesterol, although this needs confirmation.
In the C-terminal domain of PCSK9, a premature stop codon was
seeninthe New World monkeys – tamarin and duskytiti (Figure 2) –
but not in the Hominoids. As mentioned before, monkeys have
significantly lower LDL cholesterol levels than Hominoids [22]. It is
unknown whether the loss-of-function mutation in the C-terminal
domain is a random phenomenon or a common feature that
influencescholesterolmetabolism.Aprematurestopcodonmutation
in human PCSK9 (C679X) is considered to be under positive
selection, and it is speculated that loss of PCSK9 function interferes
with the life cycle of the malaria parasite through cholesterol
restriction [43,44]. The ‘‘less-is-more’’ hypothesis of Olson [45]
posits that loss of gene function during hominoid evolution may in
some cases have conferred a fitness benefit and led to adaptive
evolution that may help explain differences among primates [46].
Amino acid substitution patterns
The dN/dS ratio for the coding regions of PCSK9 across the
primate species was ,1 (cumulative dN/dS=0.186). There were
no lineages with dN/dS.1, and dN/dS ratios did not vary among
branches (P=0.480, Figure S1). This is not unexpected, as
averaging dN/dS across all sites is not a powerful test of adaptive
evolution [39]. However, the nonsynonymous substitution rate in
the C-terminal domain was significantly higher than in other
domains. The cumulative dN/dS=0.386 is higher than that in the
entire coding region (dN/dS=0.186), suggesting that different
selection pressures have acted on amino acid changes across
different functional regions of this gene.
The hypothesis of dN/dS homogeneity among branches was
rejected for the C-terminal domain (P=0.047, Figure 3), which
could reflect either relaxed selective constraint or positive selection
for amino acid substitution along one or more lineages. We were
particularly interested in two lineages in the Hominoid clade
leading to orangutan (dN/dS=infinity), as well as the common
ancestor of bonobo and gorilla (dN/dS=1.213), and tested whether
the dN/dS ratio was significantly .1 on these two branches.
Likelihood ratio tests (LRTs) from a two-ratio model revealed that
positive selection (dN/dS.1) had acted on the orangutan lineage
although the statistical evidence was marginal (P=0.087 and
P=0.090) (Table 2). However, the pattern of dN/dS heterogeneity
across lineages is consistent with a relaxed selective constraint. The
recently developed branch-site model A is powered to detect the
particularaminoacidsitesthathavebeensubjecttopositiveselection
in a given lineage (i.e., a foreground branch) [40,47], and at least five
positively selected amino acids of the C-terminal domain existed in
the lineage leading to orangutan (Table 3). No amino acids under
positive selection were detected using site models (Table 3). It should
be noted that the power of the LRTs is dependent on the number of
codingsequences[48].Wesampled14primatespeciesinHominoid,
Old World monkey, and New World monkey clades in our
phylogenetic analyses (Table 1). A greater number of the species
might have permitted more robust inferences of positive selection on
the C-terminal domain of PCSK9.
The sliding-window analysis ratio further characterized the non-
random nonsynonymous substitution along PCSK9 and dN/dS
peaks were obvious in the C-terminal domain (Figure 5). Although
the dN/dS ratio in the lineage of humans is ,1( dN/dS=0.566),
three striking peaks of dN/dS (. 4) in human lineage were noted in
the C-terminal domain. However, these peaks could be partly
explained on the basis that human PCSK9 shows very little
synonymous divergence (dS=0.003).
In the present study, we calculated the dN/dS ratios across the
phylogenetic tree using the ‘gene’ tree instead of the ‘species’ tree.
We also performed analyses using the ‘species’ tree [49], in which
bonobo is most closely related to chimpanzee and gorilla is sister to
the human/chimpanzee clade. Although the log likelihood values
(l0 for one-ratio model and l1 for free-ratio model) under the
‘species’ tree were different from that under the ‘gene’ tree, we did
not find a significant difference in the dN/dS ratio between the
‘species’ tree and ‘gene’ tree for the coding regions and C-terminal
domain. Although we did not observe dN/dS ratio .1 in the
lineage leading to bonobo or gorilla in the C-terminal domain, we
did note dN/dS=infinity in the lineage leading to orangutan. In
addition, we used the branch-site A model to test for positive
selection in the lineage leading to orangutan based on the species
tree. The 2Dl between the null model (neutral, l=21408.2) and
the alternative model (selection, l=21406.7) is 3.0 (df=2,
P,0.05) (critical value is 2.71 at 5% significance level [42]). We
detected three codon sites under positive selection (544A, 551H,
and 681S, Pb.95%) in the C-terminal domain of PCSK9 (using
BEB analysis). Zhang et al. [47] suggested a critical value of 3.84
(for P,0.05), however, such a threshold may be too conservative
for a sequence length of 200 codons [47].
Structural and functional implication of PCSK9
The correct folding of the C-terminal domain is crucial for PCSK9
function but catalytic activity is not required for PCSK9 to bind
and degrade LDL-R in cultured human hepatoma cells [50]. The
C-terminal domain of a proprotein convertase contains unique
sequences regulating their cellular localization and trafficking [51].
For example, PCSK9 exhibits a Cys-His-rich domain that is
required for cell surface binding in an LDL-R-dependent fashion
[6] and plays a role in the regulation of auto-processing of PCSK9.
The structural characteristic of C-terminal domain may determine
the colocalization of PCSK9 with LDLR at the cell surface [52] or
lead to other novel functional properties. Hence, positive selection
operating on the C-terminal domain was most likely directed at
creating novel biochemical properties.
Species-specific differences in PCSK9 expression patterns have
been noted in brain and liver among humans, chimpanzee, and
orangutan [53]. PCSK9 is transiently expressed during embryonic
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Figure 5. Sliding-window analysis of the cumulative dN/dS across
primates (black), the lineage leading to human (green), and
orangutan (blue). The gene average dS across primates is 0.5680, in
the lineage leading to human is 0.0030, and orangutan is 0.0204.
doi:10.1371/journal.pone.0001098.g005
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expression is not prominent [6,54]. Specific knockdown of Pcsk9
mRNA led to embryonic death at 4 days after fertilization in
zebrafish [54], and complete knockout of Pcsk9 in mouse led to
a ,50% reduction in circulating levels of LDL cholesterol, but did
not result in a lethal phenotype [55]. Over-expression of PCSK9
induces apoptosis in neural development [6,56], which results in
a higher percentage of differentiated neurons and promotes
cortical neurogenesis. These results indicate a novel function of
PCSK9 in central nervous system development, distinct from that
in cholesterogenic organs such as liver [54]. One could
hypothesize that relaxed selective constraint or positive selection
has operated on the C-terminal domain of PCSK9 due to the key
role of PCSK9 in early brain development.
Implications for human diseases
There is increasing interest in identifying gene loci affected by
natural selection since they are medically important [57–63]. Loss-
of-function or gain-of-function mutations in PCSK9 have been
reported to be associated with significant alterations in plasma
levels of LDL cholesterol (Figure 1). Both evolutionary conserva-
tion indicating negative purifying selection and accelerated
evolution driven by positive selection signify functionally significant
regions of the genome[64].Toassessthe potential severity of human
PCSK9 mutations, we assessed the levels of conservation or
divergence of non-synonymous mutations listed in Figure 1 by
aligning the amino acids among 14 species (Figure 2). We expected
that the amino acids known to be important for PCSK9 function (i.e.,
residues at which disease-causing mutations occur) would be highly
conserved. All gain-of-function mutations in PCSK9 leading to
hypercholesterolemia in humans are 100% conserved at the amino
acid level across all the primates we sampled. In case of loss-of-
function mutations leading to hypocholesterolemia, all but two
(E57K and Q554E) are 100% conserved across the primates.
Mutations leading to both hypercholesterolemia and hypocholester-
olemia appear to be less conserved, since four out of seven such
mutations are not all conserved, including A53V, I474V, Q554E,
and E670G. We noted a striking pattern of I474V variation (SNP
rs562556) across the primates.The ancestral state ofthe474
thamino
acid(Mor V) inNewWorld monkeysisnot cleargiven the lackofan
outgroup. The ‘V’ allelediverged to ‘I’ or ‘V’ inthe Hominoidclade,
suggesting a dynamic evolutionary history of the 474
th amino acid.
The human mutation I to V replicates the ancestral state, and the
recurrence of this ancestral state has functional consequences [65].
To survey polymorphisms within human populations, we
analyzed PCSK9 SNPs using resequenced data from 24 African-
Americans and 23 European-Americans (i.e., 47 individuals) in
SeattleSNPs database (pga.gs.washington.edu/). A total of 229
polymorphic sites in African-Americans and 125 polymorphic sites
in European-Americans were found in the human panel, eight of
which resulted in amino acid changes. In addition, an in-frame
insertion/deletion (CTG) in the signal-peptide domain was noted
in both populations. Six of the eight non-synonymous sites are
located in the putative domain and C-terminal domain (some
investigators combine these two domains as ‘C-terminal’ domain),
corresponding to the regions that have been predicted to be under
positive selection. None of the non-synonymous sites was found in
the catalytic domain. We used SIFT [66] and PolyPhen [67] to
predict the effect of the amino acid changes (Table S2). In case of
amino acid 474, the nonsynonymous substitution was predicted to
be damaging (i.e., cause functional alteration), but the derived
allele frequency of 0.79 in African-Americans and 0.87 in
European-Americans suggests that positive selection acted to
increase the frequency of this polymorphism. In humans,
a signature of recent positive selection was noted on this common
variation using long-range haplotype (LRH) test; that is, positive
selection had acted on the derived allele ‘I’ in African-Americans
and the ancestral allele ‘V’ in European-Americans (Ding and
Kullo, manuscript in revision). In addition, a signature of positive
selection on the derived allele of E670G (rs505151), which resides
in the C-terminal domain, was also noted in African-Americans.
We speculate that non-conserved mutations across the primates
might be the substrate for non-neutral evolution and responsible
for the phenotypic variation in the general population.
In conclusion, phylogenetic analysis of the cholesterol metab-
olism gene PCSK9 across a range of primates reveals lineage-
specific patterns of variation. Although the gain-of-function
mutations at PCSK9 reflect strong functional constraint and
a history of purifying selection, a signature of relaxed selective
constraint or positive selection was noted in the C-terminal
domain of PCSK9. It is possible that different modes of selection
have operated on different functional domains of PCSK9.
MATERIALS AND METHODS
Primate Genomic DNA Sources
The comparative sequences of the PCSK9 coding regions were
obtained in 14 species from three sources. First, the human
(accession no.: NM_174936) and chimpanzee (XM_427085) mRNA
sequences of PCSK9 were downloaded from NCBI (www.ncbi.nlm.
nih.gov). Next, we acquired the BAC (bacterial artificial chromo-
some) clone sequence including PCSK9 from Programs for Genomic
Application (PGA) at Berkeley (pga.lbl.gov/seq), including colobus
(AC188217), dusky titi (AC188268), squirrel monkey (AC188233),
and marmoset (AC188221). Coding regions of PCSK9 for these
species were extracted by aligning the human mRNA sequence to
the BAC sequence using the ‘sim4’ program [68]. Finally, DNA
samples for a primate panel, including rhesus macaque, pigtailed
macaque, bonobo, gorilla, chimpanzee, orangutan, tamarin, spider
monkey,woollymonkey,andlemur,wereobtainedfromCoriellCell
Repositories (Camden, NJ). The species name and scientific name
for each species are listed in Table 1.
Sequencing of PCSK9 exons from Primate Genomic
DNA
In the primate panel, PCSK9 was amplified and sequenced exon by
exon from genomic DNA with high fidelity polymerase chain
reaction (PCR). Primers and PCR conditions are listed in Table
S1. PCR products were sequenced directly in both forward and
reverse directions. Exon reads were assembled together to create
virtual transcript for each primate using the SequencherH program
(version 4.5, www.genecodes.com) and visually checked for
accuracy. The lemur PCSK9 sequence could not be obtained
due to difficulty in PCR amplification. Sequences of coding
regions for eight species in this primate panel were obtained. A
total of 2072 bp of PCSK9 coding sequence (the length is based on
the human sequence and excludes the stop codon) in 14 species
was compiled. All sequences have been submitted to the GenBank
database under the accession nos. EF692496–EF692509 (Table 1).
Detecting lineage-specific episodes of positive
selection
Sequences were aligned using ClustalW [69], followed by manual
inspection and analysis. We used the ‘HYPHY’ package to estimate
the topology of phylogenetic tree using the maximum likelihood
method [34]. Since the gene tree was different from the species tree,
analyses were done based on gene tree as well as the species tree.
Molecular Evolution of PCSK9
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substitution model by Yang [28,31,70] to test whether there was
a significant difference in dN/dS ratio (i.e., v) among lineages and
whether dN/dS was significantly .1 (i.e., positive selection) in
a given lineage. The ‘one-ratio’ model assumes the same ratio for
all branches in the phylogeny. The most general model – ‘free-
ratio’ model – assumes an independent dN/dS ratio for each
branch in the phylogeny. If there is a phylogenetic tree of many
species, this model involves as many dN/dS parameters as the
number of branches in the tree. The models used in the
phylogenetic analysis can be compared using the likelihood-ratio
test to examine interesting hypotheses [31]. The null hypothesis is
the ‘one-ratio’ model, and can be used to test whether there is
a differential dN/dS ratio among lineages. Positive selection or
relaxed selective constraint in some lineages could contribute to
the heterogeneity in the dN/dS ratio.
Detecting amino acid sites under positive selection
The above methods for lineage-specific selection assume that all
amino acid sites have the same dN/dS ratio, i.e., averages the dN/dS
ratio across all sites. Since many amino sites might be under strong
purifying selection due to functional constraint (dN/dS<zero) and
positive selection often operates episodically on a few amino acid
sites [47], it seems likely that this is a more conservative test and
amino acid sites under positive selection cannot be detected.
Several methods have been developed to address this problem,
such as the site models which allow dN/dS to vary among codons
[38,71]. In the present study, we also used an improved branch-
site likelihood method to detect positive selection at the amino acid
sites [28,40,47]. This branch-site model [28,40,47] assumed that
the branches on the phylogeny are divided a priori into foreground
(i.e, may have experienced positive selection) and background
lineages. We used the likelihood-ratio test 2 (i.e., the branch-site
test of positive selection) constructed from this branch-site model
[47]. The null hypothesis of this LRT is the branch-site model A
list above but with v2 fixed=1, which can be used to directly test
for positive selection on the foreground lineages [47]. The Bayes
empirical Bayes (BEB) approach was used to calculate the
posterior probabilities that a codon belongs to the site class of
positive selection on the foreground lineages [40]. The test should
be compared with the 50:50 mixture of point mass 0 and x2
1 (with
critical values to be 2.71 and 5.41, at the 5% and 1% significance
levels, respectively) [42]. Zhang et al [47] also suggested the use of
x2
1 distribution for assessing the significance of the test (3.84 and
5.99 at the 5% and 1% significance levels, respectively). This LRT
test seemed conservative overall, but exhibited better power in
detecting positive selection than the branch-based test [47].
We used the ‘CODEML’ program in PAML version 3.15 [72]
to calculate the dN/dS ratio and perform the maximum likelihood
phylogenetic analysis. To calculate the dN/dS ratio at lineages
(defined as all branches in the phylogeny, both terminal species
nodes and internodes), sequences associated with species-specific
premature stop codons were removed.
Sliding-window analysis of dN/dS
Sliding-window analysis of dN/dS was performed with a window
size of 90 bp (30 codons) and a sliding increment of 15 bp (5
codons). We used the approach by Choi and Lahn [73] to
calculate the dN/dS of each window as the ratio between window-
specific dN and gene-average dS, since noise in window-specific dS
can sometimes hamper the analysis. In addition, the use of gene-
average instead of window-specific dS should not introduce any
systematic bias [73].
SUPPORTING INFORMATION
Figure S1 Phylogeny of coding regions of PCSK9. PCSK9 was
resequenced from a panel of primates including Hominoids, Old
World monkeys, and New World monkeys. Branch lengths were
estimated by maximum likelihood under the free-ratio model,
which assumes an independent dN/dS ratio for each branch.
Found at: doi:10.1371/journal.pone.0001098.s001 (0.01 MB EPS)
Table S1 Polymerase chain reaction (PCR) primers and
conditions for PCSK9 exon analyses
Found at: doi:10.1371/journal.pone.0001098.s002 (0.10 MB
DOC)
Table S2 SIFT and Polyphen prediction of amino acid
polymorphisms
Found at: doi:10.1371/journal.pone.0001098.s003 (0.04 MB
DOC)
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